The relative influence of secondary versus primary prevention using the National Cholesterol Education Program Adult Treatment Panel II guidelines

Journal of the American College of Cardiology

Volumn 34, Issue 3, 1999, Pages 768-776

  Goldman, Lee ^a   Coxson, Pamela ^a   Hunink, Maria G M ^b   Goldman, Paula A ^c   Tosteson, Anna N A ^d   Mittleman, Murray ^e   Williams, Lawrence ^f   Weinstein, Milton C ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SECONDARY PREVENTION; UNITED STATES;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHOLESTEROL; CORONARY DISEASE; FEMALE; HEALTH EDUCATION; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PRACTICE GUIDELINES; PRIMARY PREVENTION; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; UNITED STATES;

EID: 0032860032     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00260-0     Document Type: Article

References (50)

1. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 269:1993;3015-3023.
2. Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction executive summary . Arch Intern Med. 151:1991;1071-1084.
3. Goldman L., Weinstein M.C., Goldman P.A., Williams L.W. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA. 265:1991;1145-1151.
4. Goldman L., Gordon D.J., Rifkind B.M., et al. Cost and health implications of cholesterol lowering. Circulation. 85:1992;1960-1968.
5. Hamilton V.H., Racicot F.E., Zowall H., et al. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease estimating the benefits of increasing HDL-C . JAMA. 273:1995;1032-1038.
6. Pedersen T.R., Kjekshus J., Berg K., et al. Cholesterol lowering and the use of healthcare resources results of the Scandinavian Simvastatin Survival Study . Circulation. 93:1996;1796-1802.
7. Johannesson M., Borgquist L., Jonsson B., Lindholm L.H. The cost effectiveness of lipid lowering in Swedish primary health care. The CELL Study Group. J Intern Med. 240:1996;23-29.
8. Pharoah P.D., Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease life table method applied to health authority population . Br Med J (Clin Res Ed). 312:1996;1443-1448.
9. Weinstein M.C., Coxson P.G., Williams L.W., et al. Forecasting coronary heart disease incidence, mortality and cost the Coronary Heart Disease Policy Model . Am J Public Health. 77:1987;1417-1426.
10. Stinnett A.A., Mittleman M.A., Weinstein M.C., et al. The cost-effectiveness of dietary and pharmacologic therapy for cholesterol reduction in adults. Gold M.R., Siegel J.E., Russell L.B., Weinstein M.C. Cost-Effectiveness in Health and Medicine. 1996;349-391 Oxford University Press, Oxford, U.K.
11. Hunink M.G.M., Goldman L., Tosteson A.N.A., et al. The recent decline in mortality from coronary heart disease, 1980-1990 the effect of secular trends in risk factors and treatment . JAMA. 277:1997;535-542.
12. Wilson P.W.F., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation. 97:1998;1837-1847.
13. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
14. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
15. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
16. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 279:1998;1615-1622.
17. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad reange of initial cholesterol levels. N Engl J Med. 229:1998;1349-1357.
18. Gould A.L., Rossouw J.E., Santanella N.C., Heyse J.F., Furburg C.D. Cholesterol reduction yields clinical benefit. Circulation. 97:1998;946-952.
19. U.S. Bureau of the Census. Projections of the Population of the United States by Age, Sex, and Race: 1982-2050. Current Population Reports. Population Estimates and Projections. Washington, DC: U.S. Government Printing Office; Series P-25. No. 922, 1982.
20. U.S. Bureau of the Census. U.S. Population Estimates by Age, Sex, Race and Hispanic Origin: 1989. Current Population Reports, Population Estimates and Projections. Washington, DC: U.S. Department of Commerce, Bureau of the Census; Series P-25, No. 1057, 1990.
21. National Center for Health Statistics. National Health and Nutrition Examination Survey, 1976-1980 [public use data tapes]. Hyattsville, MD: U.S. Department of Health and Human Services; 1990. Tape Nos. 5305 and 5301 and catalog No. 5411.
22. National Center for Health Statistics. Vital and Health Statistics. Smoking and Other Tobacco Use: United States, 1987. Hyattsville, MD: U.S. Department of Health and Human Services, Public Health Service, National Center for Health Statistics; National Health Survey Series 10, No. 169, PHS 89-1597, 1989.
23. National Health Interview Survey, United States, 1986. Hyattsville, MD: U.S. Department of Health and Human Services, Public Health Service, National Center for Health Statistics; Maryland National Health Survey Series 10, No. 164, PHS 87-1592, 1987.
24. Johnson C.L., Rifkind B.M., Sempos C.T., et al. Declining serum total cholesterol levels among US adults the National Health and Nutrition Examination Surveys . JAMA. 269:1993;3002-3008.
25. Department of Health and Human Services, 1987. The Framingham Study: an epidemiological investigation of cardiovascular disease. Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements: Framingham Heart Study, 30-year follow-up. Section 34, NIH Publication 87-2703. Bethesda, MD: National Heart, Lung, and Blood Institute.
26. Vital Statistics of the United States 1986 Volume II: Mortality, Part A . 1989;U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, Hyattsville, MD.
27. Fryback D.G., Dasbach E.J., Klein R., et al. The Beaver Dam Health Outcomes Study initial catalog of health-state quality factors . Med Decis Making. 13:1993;89-102.
28. Jacobs D., Blackburn H., Higgins M., et al. Report on the Conference on Low Cholesterol mortality associations . Circulation. 86:1992;1046-1060.
29. Neaton J.D., Blackburn H., Jacobs D., et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med. 152:1992;1490-1500.
30. Hebert P.R., Gaziano J.M., Chan K.S., Hennekens C.H. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA. 278:1997;313-321.
31. Russell L. Prevention and Medicare costs. N Engl J Med. 339:1998;1158-1160.
32. Morris C. A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy. Health Economics. 6:1997;589-601.
33. Sempos C.T., Cleeman J.I., Carroll M.D., et al. Prevalence of high blood cholesterol among US adults an update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel . JAMA. 269:1993;3009-3014.
34. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 153:1993;154-183.
35. Sytkowski P.A., D'Agostino R.B., Belandger A.J., Kannel W.B. Secular trends in long-term sustained hypertension, long-term treatment, and cardiovascular mortality. Circulation. 93:1996;697-703.
36. Edelson J.T., Weinstein M.C., Tosteson A.N.A., et al. Long-term cost-effectiveness of various initial mono-therapies for mild to moderate hypertension. JAMA. 263:1990;408-413.
37. Hulley S.B., Walsh J.M., Newman T.B. Health policy on blood cholesterol. Time to change directions. [Editorial]. Circulation. 86:1992;1026-1029.
38. Garber A.M., Browner W.S. American College of Physicians guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults. Ann Intern Med. 124:1996;515-517.
39. Stafford R.S., Blumenthal D., Pasternak R.C. Variations in cholesterol management practices of U.S. physicians. J Am Coll Cardiol. 29:1997;139-146.
40. Luepker R.V. Current status of cholesterol treatment in the community the Minnesota heart survey . Am J Med. 102:1997;37-42.
41. Goldman L., Weinstein M.C., Williams L.W. Relative impact of targeted versus populationwide cholesterol interventions on the incidence of coronary heart disease. Circulation. 80:1989;254-260.
42. Burke G.L., Sprafka J.M., Folsom A.R., et al. Trends in serum cholesterol levels from 1980 to 1987 the Minnesota Heart Study . N Engl J Med. 324:1991;941-946.
43. McGovern P.G., Pankow J.S., Shahar E., et al. Recent trends in acute coronary heart disease mortality, morbidity, medical care, and risk factors . N Engl J Med. 334:1996;884-890.
44. Johnson C.L., Rifkind B.M., Sempos C.T., et al. Declining serum total cholesterol levels among U.S. adults; the national health and nutrition examination surveys. JAMA. 269:1993;3002-3008.
45. Schectman G., Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease factors limiting achievement of lipid goals . Am J Med. 100:1996;197-204.
46. Schrott H.G., Bittner V., Vittinghoff E., et al. Adherence to national cholesterol education program treatment goals in postmenopausal women with heart disease. JAMA. 277:1997;1281-1286.
47. Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction a statement from the National Cholesterol Education Program . Circulation. 83:1991;2154-2232.
48. Tosteson A.N.A., Weinstein M.C., Hunink M.G.M., et al. Cost-effectiveness of population-wide educational approaches to reduce serum cholesterol levels. Circulation. 95:1997;24-30.
49. West of Scotland Coronary Prevention Study. Identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet. 348:1996;1339-1342.
50. Durrington P.N., Prais H., Bhatnagar D., et al. Indications for cholesterol-lowering medication comparison of risk-assessment methods . Lancet. 353:1999;278-281.